CD274 and neoplasm: Together, our results demonstrate that the combined therapy with the USP8 inhibitor, DUBs-IN-2, and anti-PD-1/PD-L1 has similar efficacy in both lung and colon cancer tumor models, indicating that the mechanism of this study should be suitable for both NSCLC and colon cancers.